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Abstract 
Maturity‑onset diabetes of the young (MODY), one of the specific types of diabetes mellitus, is a monogenetic disor‑
der characterized by an autosomal dominant (AD) inheritance and β‑cell dysfunction. To study an Indian family with 
clinical diagnosis of MODY and detect the genetic mutations in the aspect of molecular mechanism, seven blood 
samples were obtained from the diabetic patients of this pedigree and genomic DNA was extracted from peripheral 
leukocytes. The exon1, exon2 and exon4 of hepatocyte nuclear factor‑1α (HNF‑1α) gene were amplified by poly‑
merase chain reaction. Then the products were sequenced and compared with standard sequences on gene bank. 
As a result, two mutations were detected in exon1. That was CTC → CTG (Leu → Leu) in codon17 and ATC → CTC 
(Ile → Leu) in codon27. I27L was speculated to have a close relationship with the glycometabolism and the patho‑
genesis of diabetes mellitus together with the putative novel mutation existed in this Indian pedigree. Meanwhile, 
one mutation of GGG → GGC (Gly → Gly) in codon288 of exon4 was detected in the proband. No mutations were 
found in exon2 but a G → T base substitution in the intron4 region among all seven samples was detected. It may 
have some potential effects on the onset of diabetes in this family, but we do not have any evidence right now. 
Although it requires further investigation on the function of mutations found in the intron region, our research may 
provide some clue for this issue and it deserves more attention.
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Background
Maturity-onset diabetes of the young (MODY) is a 
monogenetic disorder characterized by an autosomal 
dominant (AD) inheritance and β-cell dysfunction. It is 
a genetically, metabolically and clinically heterogeneous 
type of noninsulin-dependent diabetes mellitus and is 
diagnosed by the following criteria: (1) onset of diabe-
tes ≤  age 25; (2) transmission of the disease for at least 
three continuous generations; (3) control of hyperglyce-
mia for a minimum period of 5  years without usage of 
insulin and absence of ketonuria at any time [1].
Different subtypes of MODY are caused by specific 
gene mutations. Six different genes have been con-
firmed to be responsible for the majority of MODY cases, 
according to which it is classified into MODY1–MODY6. 
For MODY2,the glucokinase gene (GCK) which encodes 
the glycolytic enzyme glucokinase and acts as a glucose-
sensor plays a key role in the regulation of glucose-stim-
ulated insulin secretion [2–4]. The other five genes which 
encode the transcriptional factor including hepatocyte 
nuclear factor-4α (HNF-4α)/(MODY1), hepatocyte 
nuclear factor-1α (HNF-1α)/(MODY3), insulin promoter 
factor-1 (IPF-1)/(MODY4), hepatocyte nuclear factor-1β 
(HNF-1β)/(MODY5) and NEUROD1 (MODY6) [5–9] 
can control the appropriate expression of β-cell. Never-
theless, there remains a portion of families whose viru-
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Methods
The proband (IV7) was admitted to our hospital because 
of polydipsia and polyuria for 5  years, with onset of 
age of 13. Five years ago, she suffered from polydip-
sia and polyuria and was diagnosed as type 2 diabetes 
(FPG  ≥10  mmol/L). Then she was treated with Met-
formin (500 mg, bid) for 8 months and FPG maintained 
to be normal. During this period, she experienced hypo-
glycemia twice. Therefore, she stopped taking tablets 
and FPG maintained 5–7  mmol/L without drugs or 
insulin for over 4  years. Two weeks before the admis-
sion to the hospital, she had a fever and suffered from 
frequent emiction, urgent emiction, aching emiction 
as well as polydipsia and polyuria. Some biochemi-
cal examinations showed as follows: (1) Routine uri-
nalysis: sugar(−), ketone(−), protein(1+). (2) FPG was 
7.4  mmol/L and OGTT2h was 12.1  mmol/L. (3) Oral 
glucose-insulin releasing test (OGIRT) showed that the 
fasting insulin level was 14.7  mmol/L; OGIRT1h, 2h 
and 3h were 98.9, 327.5 and 89.4 mmol/L, respectively. 
(4) HbA1C was 8.0  %. (5) Hepatic function tests, renal 
function tests and fasting blood lipids were normal. 
Consequently, she was diagnosed as diabetes along with 
urinary infection and treated with Metformin (500 mg, 
bid) and antibiotics. Blood glucose became normal 
10 days later. Simultaneously, the symptoms of urinary 
irritation disappeared and the urine protein returned to 
be negative.
We collected the information of the patient and her 
family members and found that it was consistent with 
autosomal dominant inheritance (Fig.  1). Meanwhile, it 
included a transmission of the disease through three gen-
erations, onset of diabetes ≤25 years (IV6 and IV7), con-
trol of hyperglycemia for a minimum period of 5  years 
without insulin (except IV6) and absence of ketonuria at 
any time. Based on the clinical characteristics, this Indian 
family was considered to be a special pedigree of MODY. 
There were eleven diabetic patients in this family and 
seven blood samples were drawn from them (Table 1).
All these seven patients were treated with hypoglyce-
mic agent (except patient IV6 who used insulin when 
suffering from diabetes at the age of 13) without keto-
sis or acidosis at any time and the FPG was controlled 
below 6.1  mmol/L. Other members in this family were 
confirmed to be normal with FPG  <6.1  mmol/L and 
2hPG  <7.77  mmol/L. Based on the clinical features, we 
are prone to consider this pedigree to be MODY3.
In order to confirm our diagnosis, the DNA sequenc-
ing was conducted. Genomic DNA was extracted from 
peripheral leukocytes of all the seven patients. Then “hot” 
exons including exon1, exon2 and exon4 which cover the 
majority of the mutations of HNF-1α gene were amplified 
by PCR using specific primers [11] (Table 2). Finally, the 
products were sequenced and compared with standard 
sequences on gene bank to find out possible mutations or 
polymorphisms which induced or related to the onset of 
diabetes in this family.
Results
Three mutations were detected in the coding regions 
of HNF-1α gene. Two of them were located in exon1 
(codon 17 and codon 27) and one of them was located 
in codon 288 of exon4 (Figs.  2, 3). CTC  →  CTG 
(Leu  →  Leu) mutation identified in codon17 (detected 
in II1, II2, III4, III5, IV6, IV7) was a silent mutation. 
ATC → CTC (Ile → Leu) mutation resided in codon27 
(detected in II2, III4, IV6, IV7) was a missense mutation. 
Another GGG  →  GGC (Gly  →  Gly) mutation located 
in codon288 (detected in the proband) was also a silent 
mutation. All these mutations have been confirmed to be 
single nucleotide polymorphisms (SNPs). No mutations 
or polymorphisms were found in exon2. However, a base 
substitution of G →  T was detected in the non-coding 
region of intron4 in all seven patients.
Fig. 1 Pedigree of this Indian family with MODY. Squares are males and circles are females. An arrow indicates the proband. Affected and unaffected 
subjects are indicated with filled and open symbols respectively
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Discussion
HNF-1α gene is located in chromosome 12q24.2 [12] 
and it plays a key role in regulating the expression of the 
genes associated with the glucose metabolism. Some 
researchers have shown that the HNF-1α gene can 
directly regulate the expressions of insulin genes by the 
promoters. Meanwhile, many enzymes associated with 
the insulin secretion or gluconeogenesis are controlled by 
the HNF-1α gene.
Shepherd [13] indicates that HNF-1α mutations are 
highly penetrant, with 63 % of mutation carriers having 
diabetes by the age of 25 years, 78.6 % by 35 years, and 
95.5 % by 55 years. Those who have reached early middle 
age without having diabetes probably represent non-pen-
etrance of the gene. These subjects frequently have a low 
body mass index, which can compensate for their β-cell 
defect by being sensitive to the insulin. In our study, five 
patients are diagnosed after the age of 30 years and two 
patients without obesity are diagnosed at a relatively old 
age (II1 and II2). We can explain it by the non-penetrance 
of the gene and the compensation for the β-cell defect. 
Another three patients (III3, III4 and III5) are overweight 
and diagnosed at a middle age. This may be due to a 
delayed diagnosis or a late onset of diabetes.
Ellard et  al. [14] find that there are about 200 muta-
tions in HNF-1α responsible for MODY3 and the SNPs 
can increase the risk of type 2 diabetes by influenc-
ing the expression of HNF-1α gene. In this research, we 
find that the I27L polymorphism of exon1 is presented 
in four patients (II2, III4, IV6, IV7). Recently, Holm-
kvist et  al. [15] prove that I27L polymorphism would 
reduce transcriptional activity in  vitro, lower glucose-
stimulated insulin secretion in  vivo, and increase the 
risk of type 2 diabetes especially in the overweighs and 
the elders. As we know, HNF-1α is biologically active in 
a dimer form. The I27L is located in the dimerization 
domain and may affect the function of the protein. Fur-
thermore, Isoleucine at position 27 is conserved among 
human, rat and mouse and it is located between two 
known MODY3 mutations (G20R and G31D). Conser-
vation among different species and the location of this 
polymorphism suggest the biologic importance of this 
amino acid. Although the I27L polymorphism is not the 
direct cause of MODY3, there is evidence suggesting the 
significant roles of I27L polymorphism in the pathogen-
esis of diabetes. Here we report an Indian family though 
Table 1 The clinical characteristics of this family





II1 Female 75 70 23.88 Drugs
II2 Male 72 50 22.60 Drugs
III3 Male 45 30 27.44 Drugs
III4 Female 50 41 26.50 Drugs
III5 Female 46 38 28.13 Drugs
IV6 Female 21 13 28.93 Insulin
IV7 Female 18 13 20.08 Drugs
Table 2 Sequences of primers used to amplify and directly sequence exons 1, 2, 4 of the human HNF-1α gene
Exon Sense primer (5′–3′) Antisense primer (5′–3′) Tm (°C) Product  
size (bp)
1 GGCAGGCAAACGCAACCCACG GAAGGGGGGCTCGTTAGGAGC 60 483
2 CATGCACAGTCCCCACCCTCA CTTCCAGCCCCCACCTATGAG 58 390
4 CAGAACCCTCCCCTTCATGCC GGTGACTGCTGTCAATGGGAC 62 397
Fig. 2 Sequences screening map. a Codon17 of exon1, an apparent 
doublet indicated C → G mutation can be seen in six members of this 
pedigree (II1, II2, III4, III5, IV6, IV7). b Codon27 of exon1, an apparent 
doublet indicated A → C mutation can be seen in four members of 
this pedigree (II2, III4, IV6, IV7). c Codon288 of exon4, an apparent 
doublet indicated G → C mutation can be seen in the proband of this 
pedigree (IV7)
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without novel mutations after amplifying exon1, exon2 
and exon4. We find I27L polymorphism in four patients 
which has been demonstrated to play a significant role in 
the β-cell function and the insulin secretion. Meanwhile, 
there may be some possible virulence mutations not yet 
discovered that have a synergetic influence on the β-cell 
function together with I27L polymorphism.
In addition, there exists a base replacement of G → T 
among all seven patients in the non-coding region of 
intron4. There are a small number of reports [14] about 
the mutations in the introns of HNF-1α gene or the influ-
ences on such mutations in the introns. The introns are 
regarded as nonsense segments and do not participate 
in encoding the protein. However, Mattick [16] indicates 
there is good evidence that introns can function as trans-
posable elements and that nuclear introns derive from 
self-splicing group II introns which then evolve in part-
nership with the spliceosome. Furthermore, the introns 
are the “introns” for some specified genes but maybe are 
the “exons” for other specified genes, so the mutations 
in the introns may probably have an effect on the course 
of mRNA splicing and processing and may ultimately 
contribute to the expression of the genes as well as the 
function of the protein. Here our report about an Indian 
MODY family and the concordance of the G → T sub-
stitution detected in all seven patients deserves more 
attention. Although it requires further investigation on 
whether the mutation found in the intron region had 
relationships with the expression of HNF-1α gene and 
the function of the protein, our research may provide 
some clue for this issue.
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